Nothing Special   »   [go: up one dir, main page]

UY26929A1 - Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis - Google Patents

Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis

Info

Publication number
UY26929A1
UY26929A1 UY26929A UY26929A UY26929A1 UY 26929 A1 UY26929 A1 UY 26929A1 UY 26929 A UY26929 A UY 26929A UY 26929 A UY26929 A UY 26929A UY 26929 A1 UY26929 A1 UY 26929A1
Authority
UY
Uruguay
Prior art keywords
methods
antiangiogen
polipeptides
angiogenesis
inhibit
Prior art date
Application number
UY26929A
Other languages
English (en)
Inventor
Ronald J Davidson
Jack Henkin
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of UY26929A1 publication Critical patent/UY26929A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

Fragmentos de proteína Kringle conjugada que se utilizan como compuestos para tratar enfermedades angiogénicas. También se revelan métodos y composiciones para inhibir enfermedades angiogénicas.
UY26929A 2000-09-29 2001-09-07 Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis UY26929A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67522600A 2000-09-29 2000-09-29
US94270401A 2001-08-31 2001-08-31

Publications (1)

Publication Number Publication Date
UY26929A1 true UY26929A1 (es) 2002-04-26

Family

ID=27101293

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26929A UY26929A1 (es) 2000-09-29 2001-09-07 Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis

Country Status (13)

Country Link
EP (1) EP1320589B1 (es)
JP (2) JP2004526416A (es)
AR (1) AR030631A1 (es)
AT (1) ATE410507T1 (es)
AU (1) AU2002211837A1 (es)
BR (1) BR0110421A (es)
CA (1) CA2420672A1 (es)
DE (1) DE60136084D1 (es)
ES (1) ES2313987T3 (es)
MX (1) MXPA03002778A (es)
PE (1) PE20020376A1 (es)
UY (1) UY26929A1 (es)
WO (1) WO2002026782A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003275473A1 (en) 2002-10-08 2004-05-04 Genencor International, Inc. Phenolic binding peptides
AU2012203658B2 (en) * 2007-01-10 2014-05-08 Protgen Ltd. Complexes comprising angiostatin and its fragments, preparation preparing methods and uses thereof
CN101219219B (zh) * 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
FR2915102B1 (fr) * 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
CN102639494B (zh) 2009-10-09 2016-11-09 扎夫根公司 砜化合物及其制备和使用方法
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
US20130316994A1 (en) 2010-11-29 2013-11-28 Zafgen, Inc. Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
KR20140006888A (ko) 2011-01-26 2014-01-16 자프겐 인크. 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
KR20140053013A (ko) 2011-05-06 2014-05-07 자프겐 인크. 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
EP2804856B1 (en) 2012-01-18 2017-03-15 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
WO2013169857A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
KR20150016534A (ko) 2012-05-09 2015-02-12 자프겐 인크. 푸마지롤형 화합물 및 이의 제조 및 사용 방법
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
JP2015536983A (ja) 2012-11-05 2015-12-24 ザフゲン，インコーポレイテッド 肥満の治療及び抑制における三環式化合物の使用
EP2916833A1 (en) 2012-11-05 2015-09-16 Zafgen, Inc. Methods of treating liver diseases
BR112015023390A2 (pt) 2013-03-14 2017-07-18 Zafgen Inc métodos para tratar de doença renal e outros distúrbios
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2204726A1 (en) * 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
JP3787157B2 (ja) * 1995-04-26 2006-06-21 ザ チルドレンズ メディカル センター コーポレイション アンジオスタチンフラグメント、アンジオスタチン凝集体および使用方法
ES2246513T3 (es) * 1996-05-03 2006-02-16 Abbott Laboratories Nuevos peptidos anti-angiogenicos, polinucleotidos que los codifican y procedimientos de inhibicion de la angiogenesis.
JP2002505338A (ja) * 1998-03-05 2002-02-19 カイロン コーポレイション 生物学的に活性な分子の血清半減期を増加するための方法
ATE297762T1 (de) * 1998-04-28 2005-07-15 Applied Research Systems Peg-lhrh analog konjugate
KR20000018933A (ko) * 1998-09-07 2000-04-06 김승수 내피세포 성장억제 활성을 가지는 사람 프로트롬빈 크링글단백질 및 이를 암호하는 유전자

Also Published As

Publication number Publication date
ES2313987T3 (es) 2009-03-16
ATE410507T1 (de) 2008-10-15
JP2008231107A (ja) 2008-10-02
AR030631A1 (es) 2003-08-27
PE20020376A1 (es) 2002-05-13
DE60136084D1 (de) 2008-11-20
EP1320589B1 (en) 2008-10-08
AU2002211837A1 (en) 2002-04-08
CA2420672A1 (en) 2002-04-04
WO2002026782A3 (en) 2003-01-16
MXPA03002778A (es) 2004-05-04
JP2004526416A (ja) 2004-09-02
EP1320589A2 (en) 2003-06-25
BR0110421A (pt) 2005-08-30
WO2002026782A2 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
UY26929A1 (es) Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
CU23213A3 (es) Difenilureas sustituidas con omega-carboxiarilo como inhibidores de raf quinasa
BR0211905A (pt) Dialdeìdos de rapamicina
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
DE60106954D1 (de) Resorcin-derivate
GT200000158A (es) Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
HN2000000051A (es) Derivados heterociclicos utiles como agentes anticancerosos
PT1255537E (pt) Inibidores da proteina farnesil transferase para tratar cancro da mama
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
NI200300045A (es) Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
ECSP003707A (es) Diazepanes
AU2002350623A1 (en) Targeted thrombosis by tissue factor polypeptides
UY26265A1 (es) Compuestos calciolíticos
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
EA200200948A1 (ru) Лечение псориаза
BR0111785A (pt) Composições e métodos para tratamento de candidìase
BR0009194A (pt) Composição do resorcinol
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
PT1276722E (pt) Inibidores de naftamidina-uroquinase
WO2002040510A3 (en) Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
SE0001631D0 (sv) New use

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150414